142 related articles for article (PubMed ID: 17478740)
1. Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada.
Yip TR; Demaerschalk BM
Stroke; 2007 Jun; 38(6):1952-5. PubMed ID: 17478740
[TBL] [Abstract][Full Text] [Related]
2. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States.
Demaerschalk BM; Yip TR
Stroke; 2005 Nov; 36(11):2500-3. PubMed ID: 16224087
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of mechanical thrombectomy plus tissue-type plasminogen activator compared with tissue-type plasminogen activator alone for acute ischemic stroke in France.
Kaboré N; Marnat G; Rouanet F; Barreau X; Verpillot E; Menegon P; Maachi I; Berge J; Sibon I; Bénard A
Rev Neurol (Paris); 2019 Apr; 175(4):252-260. PubMed ID: 30642680
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
Tan Tanny SP; Busija L; Liew D; Teo S; Davis SM; Yan B
Stroke; 2013 Aug; 44(8):2269-74. PubMed ID: 23780955
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
Fagan SC; Morgenstern LB; Petitta A; Ward RE; Tilley BC; Marler JR; Levine SR; Broderick JP; Kwiatkowski TG; Frankel M; Brott TG; Walker MD
Neurology; 1998 Apr; 50(4):883-90. PubMed ID: 9566367
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke.
Leppert MH; Campbell JD; Simpson JR; Burke JF
Stroke; 2015 Jul; 46(7):1870-6. PubMed ID: 26012639
[TBL] [Abstract][Full Text] [Related]
7. Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.
Quinn TJ; Dawson J
Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):513-22. PubMed ID: 19941428
[TBL] [Abstract][Full Text] [Related]
8. Regional Intervention of Stroke Care to Increase Thrombolytic Therapy for Acute Ischemic Stroke.
Damani RH; Anand S; Asgarisabet P; Bissell C; Savitz S; Suarez JI
Stroke; 2018 Aug; 49(8):2008-2010. PubMed ID: 29991653
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
[TBL] [Abstract][Full Text] [Related]
10. Would a Large tPA Trial for Those 4.5 to 6.0 Hours from Stroke Onset Be Good Value for Information?
Soeteman DI; Menzies NA; Pandya A
Value Health; 2017; 20(7):894-901. PubMed ID: 28712618
[TBL] [Abstract][Full Text] [Related]
11. A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke.
Kim AS; Nguyen-Huynh M; Johnston SC
Stroke; 2011 Jul; 42(7):2013-8. PubMed ID: 21636817
[TBL] [Abstract][Full Text] [Related]
12. Role of tissue plasminogen activator in acute ischemic stroke.
Hatcher MA; Starr JA
Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic impact of an alternative workflow process for stroke.
Gilbert BW; Huffman JB; Slechta J; Porter C; Gallagher JM
Am J Emerg Med; 2019 Feb; 37(2):294-297. PubMed ID: 30442431
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.
Boudreau DM; Guzauskas GF; Chen E; Lalla D; Tayama D; Fagan SC; Veenstra DL
Stroke; 2014 Oct; 45(10):3032-9. PubMed ID: 25190439
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.
Ganesalingam J; Pizzo E; Morris S; Sunderland T; Ames D; Lobotesis K
Stroke; 2015 Sep; 46(9):2591-8. PubMed ID: 26251241
[TBL] [Abstract][Full Text] [Related]
16. Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III.
Simpson KN; Simpson AN; Mauldin PD; Palesch YY; Yeatts SD; Kleindorfer D; Tomsick TA; Foster LD; Demchuk AM; Khatri P; Hill MD; Jauch EC; Jovin TG; Yan B; von Kummer R; Molina CA; Goyal M; Schonewille WJ; Mazighi M; Engelter ST; Anderson C; Spilker J; Carrozzella J; Ryckborst KJ; Janis LS; Broderick JP;
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28483774
[TBL] [Abstract][Full Text] [Related]
17. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
Xian Y; Liang L; Smith EE; Schwamm LH; Reeves MJ; Olson DM; Hernandez AF; Fonarow GC; Peterson ED
JAMA; 2012 Jun; 307(24):2600-8. PubMed ID: 22735429
[TBL] [Abstract][Full Text] [Related]
18. The Effect of tPA on Inpatient Rehabilitation after Stroke: A Cost Comparison.
Richardson M; Meyer M; Teasell R
Can J Neurol Sci; 2014 Jul; 41(4):482-5. PubMed ID: 24878473
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.
Tung CE; Win SS; Lansberg MG
Stroke; 2011 Aug; 42(8):2257-62. PubMed ID: 21719767
[TBL] [Abstract][Full Text] [Related]
20. Administration of tissue plasminogen activator for acute ischemic stroke in a rural Wisconsin hospital.
Charipar R; Charipar E
WMJ; 2008 Jul; 107(4):176-80. PubMed ID: 18702433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
